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Abstract
Background: Influencing the life-style risk-factors alcohol, body mass index (BMI), and smoking is an European
Union (EU) wide objective of public health policy. The population-level health effects of these risk-factors depend
on population specific characteristics and are difficult to quantify without dynamic population health models.
Methods: For eleven countries—approx. 80 % of the EU-27 population—we used evidence from the publicly
available DYNAMO-HIA data-set. For each country the age- and sex-specific risk-factor prevalence and the
incidence, prevalence, and excess mortality of nine chronic diseases are utilized; including the corresponding
relative risks linking risk-factor exposure causally to disease incidence and all-cause mortality.
Applying the DYNAMO-HIA tool, we dynamically project the country-wise potential health gains and losses using
feasible, i.e. observed elsewhere, risk-factor prevalence rates as benchmarks. The effects of the “worst practice”, “best
practice”, and the currently observed risk-factor prevalence on population health are quantified and expected
changes in life expectancy, morbidity-free life years, disease cases, and cumulative mortality are reported.
Results: Applying the best practice smoking prevalence yields the largest gains in life expectancy with 0.4 years for
males and 0.3 year for females (approx. 332,950 and 274,200 deaths postponed, respectively) while the worst
practice smoking prevalence also leads to the largest losses with 0.7 years for males and 0.9 year for females
(approx. 609,400 and 710,550 lives lost, respectively).
Comparing morbidity-free life years, the best practice smoking prevalence shows the highest gains for males with
0.4 years (342,800 less disease cases), whereas for females the best practice BMI prevalence yields the largest gains
with 0.7 years (1,075,200 less disease cases).
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Conclusion: Smoking is still the risk-factor with the largest potential health gains. BMI, however, has comparatively
large effects on morbidity. Future research should aim to improve knowledge of how policies can influence and
shape individual and aggregated life-style-related risk-factor behavior.
Keywords: Alcohol, BMI, Smoking, Life-style related risk-factors, Health impact assessment, Modeling
Background
Life-style related risk factors are major determinants of
morbidity and mortality within the EU. Chief among
them alcohol [1], overweight [2], and smoking [3]. Indu-
cing citizens to adopt a healthier life-style is currently a
major goal of European health policy in order to reduce
morbidity and premature mortality from chronic dis-
eases such as cardiovascular diseases, cancer, diabetes,
and chronic respiratory disease [4]. Nevertheless, WHO’s
European region still has the highest levels of smoking
and alcohol consumption in the world, and ranks second
in rates of overweight and obesity [5]. Despite some evi-
dence on long-term convergence of exposure to lifestyle-
related risk factors among European countries [6], there
are still salient differences between countries. Hence, the
comparative impact and importance of a risk factor will
differ between countries as risk factor prevalences differ
between countries. Furthermore, the very same risk fac-
tor prevalence might yield different health effects, de-
pending on a number of country specific factors. For
example, the current incidence, prevalence, or mortality
levels of related diseases, of competing but not directly
related diseases, or the population structure itself can
differ significantly, modifying the impacts of risk factors
on morbidity and mortality. Hence, identifying the con-
tribution of a modifiable risk factor and comparing it
with other risk factors in terms of potential health bene-
fits, must account for the specific context in each coun-
try. We developed a now publicly available software tool
DYNAMO-HIA (DYnamic MOdeling for Health Impact
Assessment), designed for projecting and quantifying the
effects of risk factor exposure on real-life populations. In
this paper, DYNAMO-HIA is used to quantify potential
health gains and health losses caused by a change in ei-
ther of the three risk factors: alcohol consumption, BMI
(body mass index), and smoking in eleven EU countries
(covering approx. 80 % of the EU population). This gives
country-by-country and virtually EU-wide insight for
each of these three risk factors which health gains may
be achieved and health losses might occur and, hence,
which risk factors are most promising to target and most
hazardous to neglect. Previous health impact assess-
ments focused either on specific diseases clusters (e.g.
cancers [7] or cardiovascular diseases [8]), used non-
dynamic projection methods [9] or selected age groups
[10], focused on single risk factors [11] or countries [12],
and/or used only theoretically feasible minimum risk
factors exposure levels for intervention scenarios [13].
This is—to the best of our knowledge—the first dynamic
health impact assessment [14] comparing the effects of
these three risk factors not only for life expectancy but
also jointly considering chronic obstructive pulmonary
disease (COPD), heart diseases, diabetes, and major can-
cer types across several countries.
Methods
Quantification of potential health gains and losses due
to changes in risk factor exposure requires defining
sensible counterfactual scenarios as benchmarks. Those
benchmark scenarios are compared to a reference sce-
nario, which for each country is based on the currently
observed risk factor prevalence (also known as “busi-
ness-as-usual” scenario). Hence, for each risk factor/
country combination three scenarios are dynamically
projected into the future, i.e. the “business-as-usual” sce-
nario and a “upper” exposure level and a “lower” expos-
ure level as the counterfactual scenarios that quantify
potential health gains and health losses.
Data sources
The DYNAMO-HIA project compiled a publicly avail-
able EU-wide data set of which eleven countries have
complete disease and risk factor information [15–19]
(See www.dynamo-hia.eu for full documentation). For
each country, we use age- and sex-specific data on the
population (size, projected birth numbers, and total
mortality rate)—as well as prevalences for BMI, alcohol
consumption, and smoking behavior (exception: no
smoking data for Poland). Furthermore, nine major
chronic diseases are included: ischemic heart diseases
(IHD), diabetes, COPD, stroke, and lung-, breast-, colo-
rectal, oral, and esophageal-cancer. Each disease is char-
acterized by incidence, prevalence, and excess mortality.
For stroke and IHD, excess mortality is modeled via two
elements: (a) age- and sex-dependent increases in mor-
tality when having those diseases and (b) acute increased
mortality when contracting the disease to reflect that for
those diseases mortality is higher at time of incidence.
Where appropriate, missing data have been back-
calculated using DISMOD II [20], applying the
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mathematical relationship between incidence, preva-
lence, and case-fatality-rate for chronic diseases within a
given population. In addition, DISMOD II was used to
ensure smooth and internally consistent data. Lastly, we
use data on age- and sex-specific relative risk causally
connecting the risk factors to disease incidence and the
relative risks of IHD- and stroke-incidence when having
diabetes.
Counterfactual benchmarks
Quantifying potential health gains or losses requires the
definition of counterfactual risk factor prevalences as a
benchmark. We opted for feasible prevalence rates, i.e.
empirically observed prevalence rates across countries,
to increase policy relevance of the analysis. Previous
studies often use theoretically motivated feasible
minimum risk factors exposure levels as counterfac-
tuals—such as eradication of overweight or smo-
king—that are unrealistic to achieve in the near future
by government policy. For example, a policy can only
turn a current smoker into a former smoker and not
into a never smoker Hence, (past) smoking behavior will
be contributing to the overall disease burden in a popu-
lation at least for some time.
The approach we used to construct feasible risk factor
prevalences is related to the calculation of best practice
life expectancies within the field of demography [21].
For that, we compared each age and sex group across
the eleven countries. For each particular age/sex com-
bination we selected as the counterfactual prevalence
the prevalence observed in the “best” or “worst” practice
country, by comparing the highest proportion in the
most desirable risk factor category for “best” practice
and the highest proportion in the least desirable risk fac-
tor category for “worst” practice in this particular age/
sex combination. This approach can be interpreted as a
synthetic population that at every age exhibits the “best”
(“worst”) health behavior among all feasible, i.e. empiric-
ally observed, health behaviors for this particular age
and sex. In our analysis the overweight and obesity cat-
egory in adults were based on those defined by WHO
[22]. Hence, for BMI the most desirable risk factor cat-
egory is a BMI of 25 or less (as this has a relative risk of
1 for all-cause mortality) and the least desirable risk fac-
tor category is a BMI >30 as this is a condition that
should be avoided. For smoking, the most desirable cat-
egories are never- and former-smokers (as both are be-
haviors that ought to be retained) and the least desirable
category is current-smokers (occasional and daily
smokers) when considering the relative risk for mortality
[3]. Clearly, being a never-smoker is more desirable than
being a former smoke. However, the most desirable state
a current smoker can be induced to occupy by policy is
“former smoker”. For alcohol the most desirable risk
factor categories are a consumption of pure alcohol of
<20 g/day (gram per day) and the least desirable categor-
ies are a consumption of more than 40 g/day when ac-
counting for the relative risk of overall mortality [23].
For the best practice scenario we keep the share of ab-
stainers constant as it would be unethical if a policy aims
to induce abstainers to become (light) drinkers [24]. (See
Table 1 for an example calculation and Additionla file 1
for a graphical depiction.)
Using this approach, we acknowledge that from a pol-
icy perspective the risk factor behavior of an individual
is the smallest, amenable unit of analysis: retaining desir-
able behavior and reducing non-desirable behavior. This
criterion values each individual and population equally,
i.e. age, age structure, and population size do not have
an influence. Other, health-outcome-focused approaches
to select a desirable (or undesirable) prevalence among
several observed prevalences usually bias the selection
towards the used outcome measure. For example, attrib-
utable deaths as a decision criterion would be largely de-
termined by exposure among the old as those contribute
to the majority of deaths in a population; life years lost
would shift the focus towards risk factor exposure
among the young.
Dynamic modeling
Within the DYNAMO-HIA consortium (www.dynamo-
hia.eu), we designed and implemented a publicly avail-
able software tool that quantifies the effect of changing
risk factor exposure on population health [25, 26].
DYNAMO-HIA was specifically developed to quantify
the effects of difference between one or more risk factor
exposures—such as smoking [27], alcohol consumption
[25], obesity [28], salt intake [29], physical activity [30],
or second hand smoking [31]—on different health out-
comes, such as prevalence of specific diseases, overall
mortality and summary measures of population health.
As a population health model, the DYNAMO-HIA tool
Table 1 Example of counterfactual construction
For 50 year old males, for example, the UK (United Kingdom) has the
highest proportion of individuals in the undesirable alcohol
consumption categories among the eleven countries (some 31 %
consume more than 40 g/day). Hence, the observed alcohol
consumption prevalence for this particular age/sex group is used for
constructing the worst practice counterfactual scenario for the
age- and sex group of 50 year old males. For 33 year old females, for
example, Denmark has the highest proportion of citizens with a
desirable BMI (some 80 % have a BMI < 25). Hence, the observed BMI
prevalence for this age/sex group is used for the corresponding age/sex
group in the best practice counterfactual. Often one or two countries
provide most observations for a given risk factor/sex combination.
For example, for the best practice BMI prevalence for females all
values above age 30 are taken from Denmark as those have the
highest proportion of females with a BMI < 25. In the case of
alcohol, for example, the worst practice counterfactual for males is
identical to the observed prevalence of the UK.
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allows to assess effects of risk factor changes on a real-
life population, hence, accounting for the country-
specific population composition and the incidence/
prevalence/mortality-profile [32] of relevant diseases.
Dynamic modeling assesses the development of popula-
tion health in the short- and in the long-run while ac-
counting for population aging—a process that is rapidly
taking place in most EU countries.
At the core, DYNAMO-HIA is Markov-type based
model simulating a real-life population (birth and death
but no migration). It projects the future risk factor ex-
posure and, consequently, the annual disease incidence
and resulting prevalence of chronic diseases and mortal-
ity over time, accounting for competing risks (see the
Additional file 1 for a description of the model core, an
article with a general explanation of the methodology
has been published here [33], and a an article explaining
the algorithms used has been published here [25]). For
the specification of a scenario, DYNAMO-HIA requires
information on the starting risk factor prevalence and
how risk factor exposure will develop in the future. For
every subsequent year, DYNAMO-HIA applies to each
age and sex group a probability determining the propor-
tion of individuals that will stay in this risk factor group
or will move to another risk factor group (e.g. how many
will keep their normal weight or will become overweight
or obese in the next year), and hence change the risk of
disease incidence and mortality in addition to the effect
of aging. The specification of these (future) transition
probabilities influences greatly the development of the
risk factor prevalence over time. Future individual risk
factor behavior is always embedded with uncertainty
and, hence, debatable. One approach [34]—that
DYNAMO-HIA provides—is to use net transition prob-
abilities, i.e. transition rates that keep the age-specific
risk factor prevalence constant, not taking into account
any future cohort effects. This is done for all three sce-
narios (“best”, “worst”, “business-as-usual”) in each
country/risk factor combination leading to 96 distinctive
scenarios (for Poland smoking data is not available).
Outcome measures
DYNAMO-HIA provides a wide range of outcome mea-
sures of which only three are reported here. (i) Absolute
Numbers: As migration is assumed to be zero and pro-
jected births do not differ between scenarios, the differ-
ence in population size can be interpreted as the
cumulative number of deaths postponed or lives lost
during the ten year projection period. However, absolute
numbers have to be interpreted with caution. Some of
the results can be solely driven by one or two large
countries that are more strongly affected by changing a
risk factor than many smaller countries, for example,
through a different age-structure or unequal exposure
between parts of the population.
(ii) Life expectancy (LE) as a well-established and ro-
bust summary measure of the current mortality regime
of a population that is uninfluenced by its population
size and age structure.
(iii) Morbidity-free life expectancy (MFLE), i.e. years
without chronic morbidity is calculated using the Sulli-
van method [35], in ten years from now. Like period life
expectancy, MFLE is independent of the age structure of
a population while combining current mortality and
morbidity conditions in a single summary measure. It
measures the average numbers of years a newborn can
expect to live in good health, i.e. without any of the dis-
eases included in our projection, under current
conditions.
Results
This section provides an overview of the projection re-
sults. Detailed tables are available in the Additional file 1.
Absolute numbers
Tables 2 and 3 give an overview of changes in absolute
prevalences and deaths postponed/lives lost when adopt-
ing the best and worst practice counterfactual, respect-
ively, for all countries combined (without Poland to
allow comparison across risk factors).
Adopting the best practice smoking scenario in each
country would postpone over half a million deaths as
compared to the reference scenario. In terms of disease
prevalence, BMI has the greatest potential in reducing
the absolute case load, increasing the number of healthy
people by over 1.6 million. Adopting the best practice al-
cohol prevalence would translate for females into some
130,000 deaths postponed but would also increase the
disease load substantially. This increased disease preva-
lence is partly caused by the fact that more people are
alive and, hence, susceptible to causally unrelated dis-
eases, e.g. COPD cases in the alcohol and BMI scenarios,
but also by the beneficial effect of light alcohol con-
sumption for parts of the population.
Deteriorating to the worst practice for smoking would
lead to the largest number of premature deaths with
some 1.3 million with almost equal effects for both gen-
ders. However, the number of diseased among females
would rise to 1.2 million as compared to the reference
scenario. In men, the number of diseased males exceeds
that of the reference scenario with 540,000 cases. The
reason for this seemingly gender disparity between of
additional number of deaths and disease cases when de-
teriorating the smoking prevalence to the worst practice
lies in a complex interplay of several factors. One is that
men have a 20 % higher risk for dying from smoking
than females. Another factor is that the worst practice
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counterfactuals affect the genders unequally. For large
countries—Germany, Italy, France, Spain—the number
of females smokers in the worst practice scenario in-
creases substantially among the middle aged where dis-
eases are contracted but general mortality is lower;
hence, the effect of an increased relative risk (RR)
through smoking status on the absolute number of death
is lower than at higher ages.
For BMI, the worst practice exposure would lead to a
similar increase of number of diseased (771,000 for fe-
males vs. 681,000 for males), but females would suffer
more than twice as many premature deaths than males
(140,000 vs. 70,000). This is partly explained by some
countries, in particular Germany and the UK, where in
the reference scenario the proportion of obese women
among the older females, where in absolute numbers the
majority of attributable deaths occur, is much lower than
in the worst practice scenario.
An adoption of the worst practice alcohol prevalence
would lead to an increase in the number of disease cases
and lives lost for both genders, whereas males would be
stronger affected than females. The comparatively lower
increase in IHD cases for females compared to males is
partly explained by the fact that only a daily consumption
Table 2 Comparison of best practice risk-factor exposure and reference scenario across all countriesa. Difference in disease cases by
disease and by persons with at least one disease in projection year ten and cumulative number of deaths postponed as calculated
by the difference in individuals alive between the scenarios by sex and risk-factor
Males Females
Alcohol BMI Smoking Alcohol BMI Smoking
Breast cancer n/a n/a n/a −44,650 −46,250 18,100
Colorectal cancer −40,050 −20,200 10,250 −8,150 −8,750 6,050
COPD 2,700 2,400 −154,600 3,900 3,850 −291,550
Diabetes −232,600 −481,800 46,750 82,900 −924,550 34,150
Esophageal cancer −8,350 50 −4,650 −1,550 50 −3,350
IHD −89,400 −244,900 −189,600 113,500 −304,550 −147,750
Lung cancer 500 16,900 −52,450 350 8,800 −34,750
Oral cancer −49,000 12,150 −32,900 −10,300 5,200 −8,650
Stroke −126,950 −86,750 −148,750 103,900 −147,500 −124,000
At least one of the above diseases −399,800 −595,650 −342,800 157,650 −1,075,200 −349,300
Deaths postponedb 93,750 57,500 332,950 134,050 129,750 274,200
aWithout data for Poland for to allow comparison
bCalculated as the difference in population size between the respective scenario if migration is zero and number of birth constant
Table 3 Comparison of worst practice risk-factor exposure and reference scenario across all countriesa. Difference in disease cases
by disease and by persons with at least one disease in projection year ten and cumulative number of lives lost as calculated by the
difference in individuals alive between the scenarios by sex and risk-factor
Males Females
Alcohol BMI Smoking Alcohol BMI Smoking
Breast cancer n/a n/a n/a 83,450 27,250 −47,750
Colorectal cancer 42,150 19,450 −19,500 18,650 3,300 −15,650
COPD −2,200 −2,850 250,600 −1,500 −3,400 824,450
Diabetes 92,100 619,850 −98,100 14,600 724,800 −103,550
Esophageal cancer 8,500 −100 9,900 1,200 −50 9,800
IHD 65,000 183,750 215,100 3,800 176,450 540,600
Lung cancer −300 −13,750 111,800 −50 −6,100 119,450
Oral cancer 60,950 −12,700 85,350 15,300 −4,050 357,50
Stroke 99,600 79,450 307,800 117,000 103,750 443,950
At least one of the above diseases 274,000 681,850 537,500 188,300 771,000 1,190,300
Lives lostb 110,250 68,500 609,400 69,550 138,950 710,550
aWithout data for Poland to allow comparison
bCalculated as the difference in population size between the respective scenario if migration is zero and number of birth
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of more than 60 g/day has a RR larger than one and the
proportion of females in this highest drinking category in-
creases only barely in the worst practice scenario, while it
increases considerably more in males.
Life expectancy
Figure 1 shows the differences in period life expectancy
when adopting the best and worst practice counterfac-
tual, panel (a) and (b) respectively, after ten years. Smok-
ing is the risk factor that has by far the biggest potential
to achieve total gains in LE with 0.4 years (y) for males
and 0.3y for females when all countries would adopt the
best practice prevalence and, similarly, the largest losses
with 0.7y for males and 0.9y for females when across all
countries the worst practice smoking prevalence would
be adopted. The effects of changes in alcohol and BMI
prevalence differ by sex. At the aggregated level, male
LE is more affected by alcohol than female LE. The po-
tential increase and the potential loss in LE have a mag-
nitude of 0.2y for males as compared to 0.1y for females.
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Fig. 1 Life expectancy*. a Potential gains in life expectancy. b Potential losses in life expectancy. Potential gains in life expectancy (Panel a) and
potential losses in life expectancy (Panel b) as measured by the differences in period life expectancy after ten years for each country and all
eleven countries (EU-11) combined by risk-factor and sex compared with the reference scenario. *No smoking data for Poland
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This magnitude, however, is reversed for BMI where the
potential increase and the potential loss in life expect-
ancy have a magnitude of 0.2y for females and only 0.1y
for males.
The comparatively large effect of smoking is explained
through the large relative risks of smoking on several
diseases—including lung cancer, COPD, IHD, and stro-
ke—and a large variation in smoking exposure patterns
across countries. The differences between worst practice
and best practice smoking prevalences for both genders
are considerable. Denmark, for example, has among the
60 year olds a more than three times higher female
smoking prevalence than Italy and a more than two
times higher male smoking prevalence than France. For
alcohol the range is smaller and differs by gender. In
most countries females drink in general less often haz-
ardous quantities. However, the worst practice counter-
factual–almost uniquely based on the UK prevalence—is
in comparison unusually high. For males, the differences
in the risk factor prevalence between scenarios are in
most countries generally less large in relative terms but
still sizeable in absolute terms, in particular for younger
ages, e.g. below 45. For obesity, the range between the
worst practice counterfactual and the prevalence of
obesity in the reference scenario for most countries is in
particular high for ages above 75.
Morbidity-free life expectancy
Figure 2 shows the projected differences in morbidity-
free life expectancy (MFLE).
For males, the gains and losses in morbidity-free years
differed less between risk factors as compared to those
in LE, reflecting similar effects of smoking on MFLE
than on LE, but larger effects of alcohol and BMI on
MFLE than on LE. Hence, adopting the best practice
smoking prevalence rate would lead to only to slightly
larger gains in disease-free years (0.4y) than alcohol and
BMI (both 0.3y). Deteriorating to the worst practice
prevalences for smoking would lead to a loss of 0.8
morbidity-free life years as compared to 0.3y for alcohol
and 0.4y for BMI.
For females, the higher relative importance of obesity
for MFLE gains and losses than for LE gains and losses
is most notable. Pursuing the best practice prevalence
for obesity promises gains of 0.7y without morbidity
compared to 0.4y for smoking. Furthermore, adopting
the best practice prevalence for alcohol would not lead
to any gain in years free of morbidity whereas the worst
practice would lead to a loss of 0.2y. When regressing to
the worst practice, smoking would have the largest effect
with a loss of 1.2 morbidity-free years followed by obes-
ity with 0.5 morbidity-free years. This narrowing of the
differences is partly explained through the different ef-
fects of these risk factors on health. Smoking causes
mostly illnesses with substantially higher excess mortal-
ity and hence shorter disease duration whereas obesity
increases the number of chronic diseases with compar-
ably lower excess mortality and thus longer duration.
For alcohol, it is important to note that moderate con-
sumption has beneficial effects at higher age, reducing
the incidence of a number of chronic diseases.
Discussion
For eleven EU countries, we benchmarked potential
health gains and losses by comparing the current risk
factor prevalence with a best practice and a worst prac-
tice scenario, respectively. The comparison was done
using a dynamic population health model, DYNAMO-
HIA, projecting for each country the real-life population
with the corresponding incidence/prevalence/mortality
profile of the nine included diseases for ten years into
the future, yielding a variety of health outcome
measures.
Smoking is still the most salient risk factor for both
genders in the EU. The potential gains, when adopting
the best practice, and the possible losses, when deterior-
ating towards the worst practice, are immense in terms
of both mortality and morbidity (approx. 1.3 million
lives lost over a ten year period). When comparing alco-
hol with BMI, alcohol as a factor for mortality is more
influential for males, i.e. more male deaths could be
postponed when adopting the best practice alcohol
prevalence and more male lives would be lost when de-
teriorating towards the worst practice alcohol prevalence
as compared to the respective BMI scenarios. For fe-
males however, the difference between the best practice
BMI prevalence and the worst practice BMI prevalence
has a larger effect on life expectancy across countries as
compared to the respective alcohol scenarios. For both
genders, BMI as a risk factor in terms of morbidity,
however, is weightier than alcohol in absolute prevalence
cases across countries and morbidity-free life years.
Hence, for males in some countries (e.g. Germany) tar-
geting BMI is the risk factor yielding larger gains in in-
creases in life expectancy and morbidity-free life years
than targeting alcohol.
The results of this modelling study confirm the im-
portance of life-style related risk factors on population
health for affluent countries like those included in our
analysis. By focusing on feasible risk factor prevalences,
our results are on average smaller than in studies focus-
ing on the total burden of disease attributable to these
risk factors or on all avoidable diseases [36, 37]. Never-
theless, in terms of magnitude of the expected changes
in life expectancy, our results are in line with a study dy-
namically modeling changes in life expectancy for the
population of the United States caused by a continuation
of trends in smoking and obesity [38, 39].
Lhachimi et al. BMC Public Health  (2016) 16:734 Page 7 of 11
Future research should aim to improve our knowledge
of how policies can influence and shape individual and
aggregated life-style related risk factor behavior. Our
analysis, however, cannot be used to directly inform pol-
icy action, its findings rather show where to focus ef-
forts. It would be worth to scrutinize those countries
that for some or all their population have best (or worst)
practice behavior to identify what are the differences
that could explain differences in modifiable factors.
These causes, such as tax or market regimes, could aid
future policy making tremendously [40–42].
Limitations
The main outcome measure of our study are mortality
and morbidity. Expressing the changes in mortality and
morbidity as life expectancies and morbidity-free life ex-
pectancies, respectively, allows comparisons across
countries as life expectancy is independent of the
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underlying age structure. Quantifying changes morbidity
as disease prevalence is affected by population size and
age structure. However, the morbidity measures used do
not distinguish the severity of the different diseases and
morbidity-free life expectancy only accounts for the nine
diseases projected. Although all major diseases that are
causally related to at least one of the three risk factors
are included other diseases exist that affect this measure.
For smoking a complication lies in the handling of
former-smokers as those is not a truly desirable risk fac-
tor state but current-smokers cannot go back to become
never-smokers. Although from a health perspective only
never-smoking is a seemingly desirable risk factor state,
a policy perspective must acknowledge that for many in-
dividuals becoming or staying former-smokers must be
the policy goal.
Similarly, light drinking of alcohol decreases the risk
of mortality as well as incidence of stroke and IHD as
compared to abstainers. For some countries—namely
Sweden, Germany, and Finland—adopting the best prac-
tice scenario, while increasing the overall proportion of
females with a desirable drinking behavior, leads to a de-
crease of the number of light drinkers while increasing
the numbers of abstainers. A significant limitation in the
results for alcohol, however, lies in the unspecified effect
that changes in overall alcohol consumption have on
those that do not change their consumption, e.g.
through violence or accidents committed by intoxicated
individuals. The relative risks only account for the effect
on those who drink. Thus, the causal pathway of alcohol
on health is as much a biological as a social one, making
an universally optimal consumption level and, hence,
best practice scenario difficult to define. Moreover, all
three risk-factors have effects beyond the health mea-
sures reported in this analysis, such as impacting long-
term labor market outcomes [43–45].
DYNAMO-HIA compares the effects of intervention/
policies, i.e. quantification of a reference scenario and one
or more intervention scenarios with a modified risk factor
exposure. The goal is not to project future population
health as such. For projecting future population health, ac-
curate information on incidence, prevalence, and excess
mortality data of the diseases included in the model are
needed in order to predict such future trends, while those
data in reality are embedded with uncertainty. This is
partly because of the presence of past trends which are
not exactly known. For the DYNAMO-HIA database it
was decided to include trend-free incidence/prevalence/
mortality-data partly estimated using DISMOD II soft-
ware. Such trend-free data are used as a neutral option,
because of the lack of reliable information on trends. In
view of the intended use of DYNAMO-HIA—that is,
comparing scenarios—this choice is not very significant as
the same disease data are used both in the intervention
and reference scenario(s). Therefore we do not expect that
this unavoidable compromise has an important effect on
the outcomes of our study.
We focus on a short projection span of ten years to in-
crease policy relevance of the application. Furthermore,
longer projection periods may show larger magnitudes
in terms of health outcomes, but those outcomes would
become increasingly less certain as they would be more
influenced by cohort effects. Moreover, we assume that
the change in the risk-factor prevalence in the interven-
tion scenarios takes place immediately, e.g. without any
adjustment period. A real life policy change, however,
takes time to come to full effect and potentially also in-
duces dynamic response in health behavior.
Conclusion
Employing feasible counterfactuals as benchmarks for
potential health gains and losses across eleven EU coun-
tries indicates that smoking is still the most salient risk
factors in terms of morbidity and mortality in both men
and women, with a notable exception: female morbidity
could be reduced most when focusing on BMI as a risk-
factor. For males, alcohol is more important than BMI
in terms of mortality and vice versa for females. In terms
of morbidity BMI is more important or at least equally
important as alcohol for both genders.
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